BridgeBio Pharma, Inc. — Director's Dealing 2023

May 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-05-16

Reporting Person: STEPHENSON BRIAN C (Secretary, Treasurer & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-16	Common Stock	M	44996	—	Acquired	81404	Direct
2023-05-16	Common Stock	F	20572	$14.09	Disposed	60832	Direct
2023-05-17	Common Stock	S	24424	$14.0095	Disposed	36408	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-16	Restricted Stock Units	$	M	1710	Disposed		Common Stock (1710)	Direct
2023-05-16	Restricted Stock Units	$	M	778	Disposed		Common Stock (778)	Direct
2023-05-16	Restricted Stock Units	$	M	24193	Disposed		Common Stock (24193)	Direct
2023-05-16	Restricted Stock Units	$	M	947	Disposed		Common Stock (947)	Direct
2023-05-16	Restricted Stock Units	$	M	17368	Disposed		Common Stock (17368)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 44,996 shares of Common Stock underlying the Reporting Person's RSUs.

F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022.

F4: Represents the weighted average sale price of the shares sold from $13.83 to $14.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.

F5: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F6: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F7: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F8: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F9: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.